Pharmaceutical

Top 10 pharma firms sustain volume growth as smaller rivals struggle

The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories

Kopran soars 10%, rallies 154% in FY27 so far; what's driving pharma stock?

Kopran share price: Average volumes on the counter more than doubled with a combined 13.12 million shares having changed hands on BSE and NSE.

Fake cancer drugs, ICU injections supplied to over 90 Bengaluru hospitals

Authorities are tracing an alleged interstate fake medicine network after a raid in Bidadi uncovered suspected counterfeit and expired drugs worth ₹5 crore

A dose of innovation

Pharma sector needs a supportive environment

Dadachanji Group launches Kaisha Pharma with 45-mn euros initial investment

Kaisha Pharma will manufacture ampoules, vials, prefilled syringes and cartridges, while targeting Indian and global pharmaceutical and biotechnology companies

Rubicon Research zooms 166% in CY2026; hits new high post Q1 results

Rubicon's share price hit a new high of ₹1,800 soaring 11 per cent on the BSE in Monday's intra-day deals amid heavy volume after reporting healthy earnings for Q1FY27.

GSK India aims to double revenue to ₹8K cr by FY30: MD Bhushan Akshikar

GSK India aims to double revenue to ₹8,000 crore by FY30, with oncology and adult vaccines emerging as key growth drivers alongside its general-medicines portfolio

Govt weighs incorporating trade-margin rationalisation into DPCO

No deadline set for policy; non-scheduled drugs account for 82% of market, average channel markup on common dosage forms is 43%

'India began drug discovery before China, but China has moved years ahead'

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

International business to remain key driver for Emcure Pharma in FY27

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

Zydus Life gets USFDA nod for generic indocyanine green for injection

USFDA has granted final approval to Zydus Lifesciences' generic version of IC-Green, an imaging agent used in vascular, transplant and cancer surgeries.

After sharp stock rally, valuation hurdles may cap Divi's returns

Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside

Divi's Labs rallies 5% on strong Q1; surpasses Eicher, Hindalco in mcap

In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.

Mankind Pharma Q1 result: Profit rises 29.6% to ₹568 cr, revenue up 12.9%

Profit before tax rose 42.4 per cent to ₹769 crore as expenses grew slower than revenue and finance costs declined 35.6 per cent; tax expense more than doubled

Oriflame to sell India manufacturing operations to Akums subsidiary

The Swedish beauty brand will retain its commercial operations in India while entering a long-term manufacturing and supply partnership with Akums

Cadila Pharma says no curbs on Aciloc products, affirms compliance

Cadila Pharmaceuticals said Aciloc 150+ and Aciloc 300+ remain available without any restrictions on manufacture or sale, while reaffirming compliance with regulatory requirements

Emcure Pharma makes Gennova wholly owned, names Samit Mehta CEO

Restructuring positions biotech arm to focus on biologics and biosimilar

Indian drugmakers line up for Keytruda biosimilar race as patents near end

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Indian pharma's next prescription: Specialty drugs, not just generics

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Cipla expands respiratory, specialty manufacturing across India, China, US

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets